Skip to main content
Equibles
AVTX logo

AVTX

Avalo Therapeutics, Inc.
$19.25 -0.71 (-3.56%) At close · Jul 7
Market Cap
$1.01B
Shares
52,565,572

Earnings calls and other investor events (conferences, investor days) grouped as single events — the transcript and audio, plus, for earnings calls, the 8-K earnings release and the quarter's 10-Q or 10-K, with the reported result and management tone at a glance.

Revenue & result across quarters

Revenue ($B) YoY up YoY down artefacts
LATEST ▼100% '25 Q3 25-11-06 ▼66.3% '24 Q4 25-03-20 ▲5.5% '24 Q3 24-11-07 ▼100% '24 Q2 24-08-12 ▼100% '24 Q1 24-05-13 ▼36.4% '23 Q4 24-03-29 ▼98.4% '23 Q3 23-11-09 ▼37.8% '23 Q2 23-08-03 ▼59.5% '23 Q1 23-05-04 ▲307.3% '22 Q4 23-03-29 ▲1007.3% '22 Q3 22-11-07 ▼69.2% '22 Q2 22-08-04
Annual General Meeting
Investor event
2026-06-02
2026 Annual Meeting of Stockholders
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Avalo Therapeutics, Inc. Q1 FY2026 Earnings Call
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-01-12
Avalo Therapeutics, Inc. Q4 FY2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Avalo Therapeutics, Inc. Q3 FY2025 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-2.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Avalo Therapeutics, Inc. Q2 FY2025 Earnings Call
Diluted EPS
$-1.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Avalo Therapeutics, Inc. Q1 FY2025 Earnings Call
Diluted EPS
$-1.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Avalo Therapeutics, Inc. Q4 FY2024 Earnings Call
Revenue
$192,000*
▼ 66.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Avalo Therapeutics, Inc. Q3 FY2024 Earnings Call
Revenue
$249,000
▲ 5.5% YoY
Diluted EPS
$-2.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Avalo Therapeutics, Inc. Q2 FY2024 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-14.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Avalo Therapeutics, Inc. Q1 FY2024 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-141.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Avalo Therapeutics, Inc. Q4 FY2023 Earnings Call
Revenue
$570,000*
▼ 36.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Avalo Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$236,000
▼ 98.4% YoY
Diluted EPS
$-26.83
▼ 132.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Avalo Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$643,000
▼ 37.8% YoY
Diluted EPS
$-140.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Avalo Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$475,000
▼ 59.5% YoY
Diluted EPS
$-204.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-29
Avalo Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$896,000*
▲ 307.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Avalo Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$14.95M
▲ 1007.3% YoY
Diluted EPS
$81.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Avalo Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$1.03M
▼ 69.2% YoY
Diluted EPS
$-331.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Avalo Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$1.17M
▲ 148% YoY
Diluted EPS
$-564.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-02
Avalo Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$220,000*
▼ 85.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Avalo Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$1.35M
▲ 21.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-02
Avalo Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$3.35M
▲ 150.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Avalo Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$473,000
▼ 82.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-07
Avalo Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$1.50M*
▲ 157.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Avalo Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$1.11M
▼ 49.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Avalo Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$1.34M
▼ 3.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Avalo Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$2.75M
▲ 6.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-11
Avalo Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$580,808*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1534120 CUSIP 05338F306 13F (30d) 2 filings 2 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)